Acute lymphoblastic leukemia (ALL) is a blood cancer characterized by the accumulation and proliferation of immature lymphoid progenitors (blasts). Specifically, this can be classified, at a phenotypic level, on the type of affected B or T lymphocytes.
Conventional treatments for adult patients with ALL use the combination of chemotherapeutic agents that induce complete remission (CR) in 80-90% of patients. Despite initial success, 5-years overall survival rates remain in the 40% range, as a large proportion of patients become resistant to conventional therapies or relapse.
Tiziano is responsible for investigating the correlation between the response to DNA damage and the cGAS-STING pathway in chemoresistant B-ALL cells, to establish the possible involvement of this pathway in the development of chemoresistance, with the final aim of evaluating the effect of agonists of the cGAS-STING pathway as new immunotherapeutic agents.
Tiziano graduated in Biology applied to Biomedicine at the University of Pisa with a thesis regarding PD-L1, an immune checkpoint protein, overexpressed by some tumor cell types to escape the immune system.
Tiziano is a PhD student in Biology at the University of Pisa.